Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2011. The report discloses a specific corporate transaction regarding a notifiable share interest in Theravance, Inc., rather than providing comprehensive financial results for the period.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for GSK. The only financial data disclosed relates to a specific equity purchase:
- Investment Amount: $1,298,476.53
- Shares Purchased: 58,411 shares of Theravance, Inc. Common Stock
- Price Per Share: $22.23
- Transaction Date: November 1, 2011
Material Changes
The material change reported is an increase in GSK's ownership stake in Theravance, Inc. Following the purchase, GSK's total holding stands at 15,725,953 shares, representing approximately 19.01% of Theravance's outstanding capital stock (based on 82,666,224 shares outstanding as of September 30, 2011). This purchase was executed to maintain GSK's ownership percentage in light of Theravance's net option exercise and equity vesting activity in the preceding quarter.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the share purchase. The transaction is noted as disclosable under Securities and Exchange Commission rules.
Investor Verification Points
- Verify the current ownership percentage of GSK in Theravance, Inc. against the reported 19.01%.
- Confirm the total number of Theravance shares outstanding as of the most recent reporting date to validate the percentage calculation.
- Review subsequent filings to determine if this transaction triggers any additional reporting thresholds or changes in the nature of the investment relationship.